Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,666

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Biomarkers in Cancer Staging, Prognosis and Treatment Selection

Ludwig, Joseph A., Weinstein, John N.·2005·Nature Reviews Cancer
DOI 10.1038/nrc1739
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrc1739

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 137

  1. Sobin, L. H. TNM: evolution and relation to other prognostic factors. Semin. Surg. Oncol. 21, 3–7 (2003). Historical perspective of the TNM staging guidelines. · doi:10.1002/ssu.10014
  2. Hammond, M. E. & Taube, S. E. Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. Semin. Oncol. 29, 213–221 (2002). Provides useful guidelines for the discovery, evaluation and validation of clinical biomarkers. · DOI
  3. Negm, R. S., Verma, M. & Srivastava, S. The promise of biomarkers in cancer screening and detection. Trends Mol. Med. 8, 288–293 (2002). · DOI
  4. Nishizuka, S. et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res. 63, 5243–5250 (2003). Clear demonstration that numerous genomic, proteomic and tissue-based arrays can be used in concert to distinguish between colon and ovarian carcinomas.
  5. Leong, P. P. et al. Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J. Natl Cancer Inst. 90, 972–977 (1998). · DOI
  6. Califano, J. et al. Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. J. Natl Cancer Inst. 91, 599–604 (1999). · DOI
  7. Califano, J. et al. Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin. Cancer Res. 6, 347–352 (2000).
  8. Ma, X. et al. Gene expression profiles of human breast cancer progression. Proc. Natl Acad. Sci. USA 100, 5974–5979 (2003). · DOI · Paper page
  9. Abulafia, O. & Sherer, D. M. Automated cervical cytology: meta-analyses of the performance of the PAPNET system. Obst. Gynecol. Surv. 54, 253–264 (1999). · DOI
  10. Destounis, S. V. et al. Can computer-aided detection with double reading of screening mammograms help decrease the false-negative rate? Initial experience. Radiology 232, 578–584 (2004). · DOI
  11. Awai, K. et al. Pulmonary nodules at chest CT: effect of computer-aided diagnosis on radiologists' detection performance. Radiology 230, 347–352 (2004). · DOI · Paper page
  12. Erickson, B. J. & Bartholmai, B. Computer-aided detection and diagnosis at the start of the third millennium. J. Digit. Imaging 15, 59–68 (2002). · DOI
  13. American Joint Committee on Cancer & American Cancer Society. AJCC Cancer Staging Handbook: from the AJCC Cancer Staging Manual (eds Greene, F. L. et al.) (Springer, New York, 2002). AJCC guidelines for cancer staging.
  14. McQuade, P. & Knight, L. C. Radiopharmaceuticals for targeting the angiogenesis marker αvβ3 . Q. J. Nucl. Med. 47, 209–220 (2003).
  15. Blankenberg, F. G. et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc. Natl Acad. Sci. USA 95, 6349–6354 (1998). · DOI · Paper page
  16. Kuge, Y. et al. Feasibility of 99mTc-annexin V for repetitive detection of apoptotic tumor response to chemotherapy: an experimental study using a rat tumor model. J. Nucl. Med. 45, 309–312 (2004).
  17. Krohn, K. A. Evaluation of alternative approaches for imaging cellular growth. Q. J. Nucl. Med. 45, 174–178 (2001).
  18. Kostakoglu, L., Agress, H. Jr & Goldsmith, S. J. Clinical role of FDG PET in evaluation of cancer patients. Radiographics 23, 315–340 (2003). · DOI · Paper page
  19. Kostakoglu, L. & Goldsmith, S. J. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J. Nucl. Med. 44, 224–239 (2003).
  20. Britz-Cunningham, S. H. & Adelstein, S. J. Molecular targeting with radionuclides: state of the science. J. Nucl. Med. 44, 1945–1961 (2003).
  21. Agrawal, M. et al. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin. Cancer Res. 9, 650–656 (2003).
  22. Revillion, F., Bonneterre, J. & Peyrat, J. P. ERBB2 oncogene in human breast cancer and its clinical significance. Eur. J. Cancer 34, 791–808 (1998). · DOI · Paper page
  23. Press, M. F. et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res. 54, 5675–5682 (1994).
  24. Singletary, S. E. et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J. Clin. Oncol. 20, 3628–3636 (2002). · DOI · Paper page
  25. Druker, B. J. et al. Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038–1042 (2001). · DOI · Paper page
  26. Balmain, A., Gray, J. & Ponder, B. The genetics and genomics of cancer. Nature Genet. 33 (Suppl.), 238–244 (2003). · DOI · Paper page
  27. Kaneda, H. et al. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. Lung Cancer 46, 247–254 (2004). · doi:10.1016/j.lungcan.2004.04.032
  28. Ravdin, P. M. et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J. Clin. Oncol. 19, 980–991 (2001). · DOI · Paper page
  29. Relling, M. & Dervieux, T. Pharmacogenetics and cancer therapy. Nature Rev. Cancer 1, 99–108 (2001). · DOI
  30. Lenz, H. J. The use and development of germline polymorphisms in clinical oncology. J. Clin. Oncol. 22, 2519–2521 (2004). · doi:10.1200/jco.2004.04.900
  31. Leon, S. A., Shapiro, B., Sklaroff, D. M. & Yaros, M. J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37, 646–650 (1977).
  32. Kahn, H. J. et al. Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: correlation with disease stage. Breast Cancer Res. Treat. 86, 237–247 (2004). · DOI
  33. Stathopoulou, A. et al. Real-time quantification of CK-19 mrna-positive cells in peripheral blood of breast cancer patients using the lightcycler system. Clin. Cancer Res. 9, 5145–5151 (2003).
  34. Hoon, D. S. et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 60, 2253–2257 (2000).
  35. Muller, V. & Pantel, K. Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives. Breast Cancer Res. 6, 258–261 (2004). · doi:10.1186/bcr942
  36. Pantel, K. & Brakenhoff, R. H. Dissecting the metastatic cascade. Nature Rev. Cancer 4, 448–456 (2004). · DOI · Paper page
  37. Meng, S. et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 10, 8152–8162 (2004). · DOI · Paper page
  38. Brennon, J. A. et al. Molecular assesment of histopathological staging in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 332, 429–435 (1995). · DOI · Paper page
  39. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88, 323–331 (1997). · DOI · Paper page
  40. Nigro, J. M., et al. Mutations in the p53 gene occur in diverse tumor types. Nature 342, 705–708 (1989). · DOI · Paper page
  41. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786–792 (2005). · DOI · Paper page
  42. Merlo, A. et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med. 1, 686–692 (1995). · DOI · Paper page
  43. Herman, J. G. et al. Silencing of the VHL tumor-suppressor gene by dna methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91, 9700–9704 (1994). · DOI · Paper page
  44. Jenuwein, T. & Allis, C. Translating the histone code. Science 293, 1074–1080 (2001). · DOI · Paper page
  45. Esteller, M., Corn, P. G., Baylin, S. B. & Herman, J. G. A gene hypermethylation profile of human cancer. Cancer Res. 61, 3225–3229 (2001).
  46. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D. & Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93, 9821–9826 (1996). · DOI · Paper page
  47. Frommer, M. et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual dna strands. Proc. Natl Acad. Sci. USA 89, 1827–1831 (1992). · DOI · Paper page
  48. Jeronimo, C. et al. Quantitation of GTSP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl Cancer Inst. 93, 1747–1752 (2001). · DOI · Paper page
  49. Rosas, S. L. et al. Promoter hypermethylation patterns of p16, o6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 61, 939–942 (2001).
  50. Belinsky, S. A. et al. Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl Acad. Sci. USA 95, 11891–11896 (1998). · DOI · Paper page
  51. Palmisano, W. A. et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60, 5954–5958 (2000).
  52. Ahrendt, S. A. et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J. Natl Cancer Inst. 91, 332–339 (1999). · DOI · Paper page
  53. Ramirez, J. L. et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett. 193, 207–216 (2003). · DOI
  54. Usadel, H. et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res. 62, 371–375 (2002).
  55. Valenzuela, M. T. et al. Assessing the use of p16INK4a promoter gene methylation in serum for detection of bladder cancer. Eur. Urol. 42, 622–630 (2002). · DOI
  56. Nakayama, H. et al. Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients. Int. J. Cancer 105, 491–493 (2003). · DOI
  57. Yamaguchi, S., Asao, T., Nakamura, J. I., Ide, M. & Kuwano, H. High frequency of DAP-kinase gene promoter methylation in colorectal cancer specimens and its identification in serum. Cancer Lett. 194, 99–105 (2003). · DOI
  58. Esteller, M. et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl J. Med. 343, 1350–1354 (2000). · DOI · Paper page
  59. Weinstein, J. N. Pharmacogenomics — teaching old drugs new tricks. N. Engl. J. Med. 343, 1408–1409 (2000). · DOI
  60. Esteller, M. DNA methylation and cancer therapy: new developments and expectations. Curr. Opin. Oncol. 17, 55–60 (2005). · DOI · Paper page
  61. Cheng, J. C. et al. Preferential response of cancer cells to zebularine. Cancer Cell 6, 151–158 (2004). · DOI · Paper page
  62. Piekarz, R. & Bates, S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr. Pharm. Des. 10, 2289–2298 (2004). · DOI
  63. Piekarz, R. L. et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103, 4636–4643 (2004). · DOI · Paper page
  64. Mischel, P. S., Cloughesy, T. F. & Nelson, S. F. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nature Rev. Neurosci. 5, 782–792 (2004). · DOI · Paper page
  65. Gray, J. W. & Collins, C. Genome changes and gene expression in human solid tumors. Carcinogenesis 21, 443–452 (2000). · DOI · Paper page
  66. Velculescu, V. E., Zhang, L., Vogelstein, B. & Kinzler, K. W. Serial analysis of gene expression. Science 270, 484–487 (1995). · DOI · Paper page
  67. Weigl, B. H., Bardell, R. L. & Cabrera, C. R. Lab-on-a-chip for drug development. Adv. Drug. Deliv. Rev. 55, 349–377 (2003). · DOI · Paper page
  68. Weinstein, J. N. et al. An information-intensive approach to the molecular pharmacology of cancer. Science 275, 343–349 (1997). · DOI · Paper page
  69. Papin, J. A, Hunter, T., Palsson, B. O. & Subramaniam, S. Reconstruction of cellular signalling networks and analysis of their properties. Nature Rev. Mol. Cell Biol. 6, 99–111 (2005). · DOI · Paper page
  70. Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C. & Liotta, L. A. Clinical proteomics: translating benchside promise into bedside reality. Nature Rev. Drug Discov. 1, 683–695 (2002). Comprehensive review of clinical proteomic technologies and associated pattern-based protein markers. · DOI · Paper page
  71. Perou, C. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000). · DOI · Paper page
  72. Sorlie, T., Perou, C., Brown, P., Botstein, D. & Borresen-Dale, A. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869–10874 (2001). · DOI · Paper page
  73. Sotiriou, C. et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA 100, 10393–10398 (2003). · DOI · Paper page
  74. van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999–2009 (2002). · DOI · Paper page
  75. Chang, J. C. et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362–369 (2003). · DOI · Paper page
  76. Sotiriou, C. et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 4, R3 (2002). · DOI
  77. Ramaswamy, S., Ross, K., Lander, E. & Golub, T. A molecular signature of metastasis in primary solid tumors. Nature Genet. 33, 49–54 (2003). · DOI · Paper page
  78. Rosell, R. et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 10, 1318–1325 (2004). · DOI · Paper page
  79. Salonga, D. et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6, 1322–1327 (2000).
  80. Bittner, M. et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536–540 (2000). · DOI · Paper page
  81. Carr, K. M., Bittner, M. & Trent, J. M. Gene-expression profiling in human cutaneous melanoma. Oncogene 22, 3076–3080 (2003). · DOI
  82. Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531–537 (1999). · DOI · Paper page
  83. Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000). · DOI · Paper page
  84. Lossos, I. S. et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc. Natl Acad. Sci. USA 99, 8886–8891 (2002). · DOI · Paper page
  85. Garber, M. E. et al. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl Acad. Sci. USA 98, 13784–13789 (2001). · DOI · Paper page
  86. Best, C. J. et al. Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis. Diagn. Mol. Pathol. 12, 63–70 (2003). · doi:10.1097/00019606-200306000-00001
  87. Zou, T. T. et al. Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene 21, 4855–4862 (2002). · DOI
  88. Zhou, G. et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol. Cell. Proteomics 1, 117–124 (2002). · DOI · Paper page
  89. Nishizuka, S. et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl Acad. Sci. USA 100, 14229–14234 (2003). · DOI · Paper page
  90. Paweletz, C. P. et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981–1989 (2001). · DOI · Paper page
  91. Verma, M., Wright, G. L. Jr, Hanash, S. M., Gopal-Srivastava, R. & Srivastava, S. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Ann. NY Acad. Sci. 945, 103–115 (2001). · DOI
  92. Wulfkuhle, J. D., Liotta, L. A. & Petricoin, E. F. Proteomic applications for the early detection of cancer. Nature Rev. Cancer 3, 267–275 (2003). · DOI · Paper page
  93. Sano, T., Smith, C. L. & Cantor, C. R. Immuno-PCR: very sensitive antigen detection by means of specific antibody–DNA conjugates. Science 258, 120–122 (1992). · DOI · Paper page
  94. Nam, J. M., Thaxton, C. S. & Mirkin, C. A. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 301, 1884–1886 (2003). · DOI · Paper page
  95. Service, R. F. American Chemical Society Meeting. Tiny transistors scout for cancer. Science 300, 242–243 (2003).
  96. Seydel, C. Quantum dots get wet. Science 300, 80–81 (2003). · DOI
  97. Wu, X. et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nature Biotechnol. 21, 41–46 (2003). · DOI · Paper page
  98. Ben-Ari, E. T. Nanoscale quantum dots hold promise for cancer applications. J. Natl Cancer Inst. 95, 502–504 (2003). · doi:10.1093/jnci/95.7.502
  99. Igor, M. et al. Self-assembled nanoscale biosensors based on quantum dot FRET donors. Nature Mater. 2, 630–638 (2003). · DOI · Paper page
  100. Wulfkuhle, J. D. et al. Proteomics of human breast ductal carcinoma in situ. Cancer Res. 62, 6740–6749 (2002).
  101. Wulfkuhle, J. D. et al. New approaches to proteomic analysis of breast cancer. Proteomics 1, 1205–1215 (2001). · doi:10.1002/1615-9861(200110)1:10<1205::aid-prot1205>3.0.co;2-x
  102. Jones, M. B. et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2, 76–84 (2002). · DOI · Paper page
  103. Patel, V., Leethanakul, C. & Gutkind, J. S. New approaches to the understanding of the molecular basis of oral cancer. Crit. Rev. Oral Biol. Med. 12, 55–63 (2001). · doi:10.1177/10454411010120010401
  104. Ornstein, D. K. et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 21, 2235–2242 (2000). · doi:10.1002/1522-2683(20000601)21:11<2235::aid-elps2235>3.0.co;2-a
  105. Barker, P. E. Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST). Ann. NY Acad. Sci. 983, 142–150 (2003). · DOI
  106. Ransohoff, D. F. Rules of evidence for cancer molecular marker discovery and validation. Nature Rev. Cancer 4, 309–314 (2004). Effectively summarizes the problem of data overfitting in discovery-based research and the need for 'rules of evidence' to ensure clinical validity. · DOI · Paper page
  107. Gutman, S. Regulatory issues in tumor marker development. Semin. Oncol. 29, 294–300 (2002). Examines the regulatory environment surrounding biomarker approval by the FDA and CMS. · doi:10.1053/sonc.2002.33140
  108. Taube, S. E. & Freiberg, G. P. Regulatory issues related to marker development. Urol. Oncol. 5, 214–216 (2000). · doi:10.1016/s1078-1439(00)00076-4
  109. Hackett, J. L. & Lesko, L. J. Microarray data — the US FDA, industry and academia. Nature Biotechnol. 21, 742–743 (2003). · doi:10.1038/nbt0703-742
  110. Mendelsohn, A. R. & Brent, R. Postgenomic protein analysis: the next bend in the river. Nature Biotechnol. 16, 520–521 (1998). · doi:10.1038/nbt0698-520
  111. Robson, M. E. et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 6, R8–R17 (2004). · DOI · Paper page
  112. Einspahr, J. G. et al. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials. Cancer Epidemiol. Biomarkers Prev. 6, 37–48 (1997).
  113. Togashi, K. Ovarian cancer: the clinical role of US, CT, and MRI. Eur. Radiol. 13 (Suppl. 4), L87–L104 (2003). · doi:10.1007/s00330-003-1964-y
  114. Schlieman, M. G., Ho, H. S. & Bold, R. J. Utility of tumor markers in determining resectability of pancreatic cancer. Arch. Surg. 138, 951–956 (2003). · DOI
  115. Depres-Brummer, P. et al. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer. J. Cancer Res. Clin. Oncol. 121, 419–422 (1995). · doi:10.1007/bf01212949
  116. Duncan, J. L., Price, A. & Rogers, K. The use of CA15.3 as a serum tumour marker in breast carcinoma. Eur. J. Surg. Oncol 17, 16–19 (1991).
  117. Gion, M. et al. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients. Cancer J. 7, 181–190 (2001).
  118. Chang, B. L. et al. Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk. Int. J. Cancer 106, 375–378 (2003). · DOI
  119. Lee, S. G. et al. Genetic polymorphisms of XRCC1 and risk of gastric cancer. Cancer Lett. 187, 53–60 (2002). · doi:10.1016/s0304-3835(02)00381-6
  120. Petrij-Bosch, A. et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nature Genet. 17, 341–345 (1997). · DOI · Paper page
  121. Newman, B. et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279, 915–921 (1998). · DOI · Paper page
  122. Wu, X. et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J. Natl Cancer Inst. 94, 681–690 (2002). · DOI
  123. Bonnen, P. E., Wang, P. J., Kimmel, M., Chakraborty, R. & Nelson, D. L. Haplotype and linkage disequilibrium architecture for human cancer-associated genes. Genome Res. 12, 1846–1853 (2002). · DOI
  124. Hoque, M. O., Lee, C. C., Cairns, P., Schoenberg, M. & Sidransky, D. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res. 63, 2216–2222 (2003).
  125. Janne, P. A. et al. High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene 23, 2716–2726 (2004). · DOI
  126. Boshoff, C. et al. Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nature Med. 1, 1274–1278 (1995). · DOI · Paper page
  127. To, E. W. H. et al. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin. Cancer Res. 9, 3254–3259 (2003).
  128. Leung, S. F. et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 98, 288–291 (2003). · DOI
  129. Mueller, N. Overview: viral agents and cancer. Environ. Health Perspect. 103 (Suppl. 8), 259–261 (1995).
  130. Koutsky, L. A. et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645–1651 (2002). · DOI · Paper page
  131. Pellet, C. et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J. Invest. Dermatol. 117, 858–863 (2001). · doi:10.1046/j.0022-202x.2001.01465.x
  132. Polyak, K. et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nature Genet. 20, 291–293 (1998). · DOI · Paper page
  133. Bianchi, N. O., Bianchi, M. S. & Richard, S. M. Mitochondrial genome instability in human cancers. Mutat. Res. 488, 9–23 (2001). · DOI
  134. Welter, C., Kovacs, G., Seitz, G. & Blin, N. Alteration of mitochondrial DNA in human oncocytomas. Genes Chromosomes Cancer 1, 79–82 (1989). · DOI
  135. Fliss, M. S. et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 287, 2017–2019 (2000). · DOI · Paper page
  136. Weinstein, J. N. Fishing expeditions. Science 282, 628–629 (1998). · doi:10.1126/science.282.5389.627g
  137. Weinstein, J. N. 'Omic' and hypothesis-driven research in the molecular pharmacology of cancer. Curr. Opin. Pharmacol. 2, 361–365 (2002). · DOI

Cited by

See all 1,666

Metadata

Authors
Ludwig, J. A., & Weinstein, J. N.
Venue
Nature Reviews Cancer
Publisher
Springer Science and Business Media LLC
Published
2005-10-20
Volume
5
Issue
11
Pages
845-856
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
DOI
10.1038/nrc1739
OpenAlex
W2126415088
Cited by
1,666
References
7
FWCI
2.61
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biomarkers in Cancer Staging, Prognosis and Treatment Selection. https://app.cochat.ai/papers/10.1038/nrc1739
The paper
Ludwig, J. A., & Weinstein, J. N. (2005). Biomarkers in Cancer Staging, Prognosis and Treatment Selection. Nature Reviews Cancer. https://doi.org/10.1038/nrc1739

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.